Perrigo (PRGO)
(Delayed Data from NYSE)
$27.69 USD
-0.49 (-1.74%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.69 USD
-0.49 (-1.74%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Zacks News
Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat
by Zacks Equity Research
Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.
Perrigo (PRGO) Lags Q2 Earnings Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -2.27% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for REGL
QuidelOrtho (QDEL) Q2 Earnings Miss Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.55% and 7.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brainsway Ltd. Sponsored ADR (BWAY) Stock Jumps 9.4%: Will It Continue to Soar?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
by Zacks Equity Research
The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.
Why Is Perrigo (PRGO) Up 13.4% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
by Zacks Equity Research
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
Perrigo (PRGO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -21.43% and 1.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Brookdale Senior Living (BKD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Brookdale (BKD) delivered earnings and revenue surprises of -45.95% and 1.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Perrigo (PRGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Perrigo (PRGO) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Perrigo (PRGO) Q4 Earnings Beat as Cough & Cold Sales Recover
by Zacks Equity Research
Perrigo (PRGO) reports encouraging fourth-quarter 2021 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Stock gains.
Perrigo (PRGO) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Hanger (HNGR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hanger (HNGR) delivered earnings and revenue surprises of 5.26% and 0.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More
by Kinjel Shah
Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.
3 Medical Device Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
The Medical device companies' Q4 results are likely to reflect base business recovery on a year-over-year basis. Let's see how PRGO, COO and SGHT are poised ahead of their earnings releases.
Is a Beat Likely for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.